AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17678567 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil/evening primrose oil (FSO/EPO) blend (456 mg DHA/d and 353 mg GLA/d)
Number of subjects: 20
Study 17678567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mixture of habitual dietary fatty acids)
Number of subjects: 20
Study 15972565 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotics
Number of subjects: 807
Study 15972565 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotics
Number of subjects: 807
Study 15972565 — intervention group
Group type: COMPARATOR
Intervention: No offer of antibiotics
Number of subjects: 807
Study 15972565 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet
Number of subjects: 807
Study 12588776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 11
Study 12588776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11234243 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychobiological nutritional rehabilitation (PNR)
Number of subjects: 40
Study 11234243 — intervention group
Group type: COMPARATOR
Intervention: Traditional nutritional rehabilitation (TNR)
Number of subjects: 40
Study 8901654 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 (ET-1) infused intravenously at rates of 0.2, 1, and 8 pmol/kg per minute for 10-20 minutes.
Number of subjects: 0
Study 8901654 — intervention group
Group type: EXPERIMENTAL
Intervention: Big endothelin-1 infused intravenously at rates of 0.2, 1, and 8 pmol/kg per minute for 20 minutes.
Number of subjects: 0
Study 1856148 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing regimen
Number of subjects: 100
Study 1856148 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily dosing regimen
Number of subjects: 100
Study 6136101 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine 0.01 mg
Number of subjects: 12
Study 6136101 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide tromethamine 0.1 mg
Number of subjects: 12
Study 6136101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31176362 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated validation
Number of subjects: 0
Study 31176362 — intervention group
Group type: COMPARATOR
Intervention: Manual validation
Number of subjects: 0
Study 28711556 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 1175
Study 28711556 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1175
Study 27633147 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop gastric electrical stimulation (CLGES)
Number of subjects: 160
Study 27633147 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric band (LAGB)
Number of subjects: 160
Study 24768290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (100 mg)
Number of subjects: 41
Study 24768290 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac (30 mg)
Number of subjects: 41
Study 23021528 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine hydrochloride with 1:100,000 epinephrine
Number of subjects: 120
Study 23021528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine
Number of subjects: 120
Study 23021528 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 120
Study 23021528 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 120
Study 19898218 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIntron 0.5 microg/kg
Number of subjects: 259
Study 19898218 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIntron 1.0 microg/kg
Number of subjects: 259
Study 19898218 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIntron 1.5 microg/kg
Number of subjects: 259
Study 19898218 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIntron 3.0 microg/kg
Number of subjects: 259
Study 19898218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 19898218 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIntron (all doses)
Number of subjects: 259
Study 17325604 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Gag/Pol DNA vaccine
Number of subjects: 21
Study 17325604 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg Gag/Pol DNA vaccine
Number of subjects: 21
Study 17325604 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg Gag/Pol DNA vaccine
Number of subjects: 21
Study 17325604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17325604 — intervention group
Group type: EXPERIMENTAL
Intervention: Gag/Pol DNA vaccine (all doses)
Number of subjects: 21
Study 12973849 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-drugs-in-1-day regimen
Number of subjects: 70
Study 12973849 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (lomustine, vincristine, and prednisone)
Number of subjects: 70
Study 10374248 — intervention group
Group type: EXPERIMENTAL
Intervention: Banxia Houpo Tang (BHT) 7.5 g per day for four weeks
Number of subjects: 32
Study 10374248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10374248 — intervention group
Group type: EXPERIMENTAL
Intervention: Banxia Houpo Tang (BHT)
Number of subjects: 32
Study 8678102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2 g thrice daily)
Number of subjects: 216
Study 8678102 — intervention group
Group type: COMPARATOR
Intervention: Comparator regimens (ceftazidime 2 g thrice daily or piperacillin + gentamicin 3 g every 4 hours + 1.5 mg/kg every 8 hours)
Number of subjects: 216
Study 1798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 1798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0
Study 1798839 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 7082781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet dosage forms (three different tablet products)
Number of subjects: 12
Study 7082781 — intervention group
Group type: COMPARATOR
Intervention: Reference solution
Number of subjects: 12
Study 30673051 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 110
Study 30673051 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 110
Study 30673051 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 110
Study 30673051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 29226727 — intervention group
Group type: EXPERIMENTAL
Intervention: RA patients
Number of subjects: 85
Study 29226727 — intervention group
Group type: COMPARATOR
Intervention: IL1RN*2/2 homozygous genotype in CS
Number of subjects: 85
Study 29226727 — intervention group
Group type: COMPARATOR
Intervention: IL1RN*2/2 genotype in CS
Number of subjects: 85
Study 29226727 — intervention group
Group type: EXPERIMENTAL
Intervention: RA patients with IL1RN*long/long genotype
Number of subjects: 85
Study 29226727 — intervention group
Group type: COMPARATOR
Intervention: Carriers of IL1RN*2/2 genotype
Number of subjects: 85
Study 26343591 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS (1.5 mA)
Number of subjects: 45
Study 26343591 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 45
Study 23144444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus best supportive care (BSC)
Number of subjects: 511
Study 23144444 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 511
Study 21608065 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exercise program (training group, N = 17)
Number of subjects: 29
Study 21608065 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 12)
Number of subjects: 29
Study 19663099 — intervention group
Group type: EXPERIMENTAL
Intervention: antihyperlipidemic decoction
Number of subjects: 77
Study 19663099 — intervention group
Group type: COMPARATOR
Intervention: zhinbiticose (western medicine)
Number of subjects: 77
Study 16962526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavaterm thermal balloon endometrial ablation
Number of subjects: 51
Study 16962526 — intervention group
Group type: COMPARATOR
Intervention: Hysteroscopic endometrial resection
Number of subjects: 51
Study 16085252 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg loading dose intrarectally, followed by 650 mg every 4 hours for 48 hours)
Number of subjects: 65
Study 16085252 — intervention group
Group type: COMPARATOR
Intervention: Placebo (loading dose and subsequent doses as a placebo suppository)
Number of subjects: 65
Study 10702890 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol 100 mg twice daily for 13 days
Number of subjects: 15
Study 10702890 — intervention group
Group type: COMPARATOR
Intervention: placebo twice daily for 13 days
Number of subjects: 15
Study 8724092 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fat transplantation
Number of subjects: 99
Study 8724092 — intervention group
Group type: COMPARATOR
Intervention: Standard operation without fat transplantation
Number of subjects: 99
Study 1680095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 7037159 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (5000 rad in five weeks, 200 rad fractions, directed to the primary tumor area and neck)
Number of subjects: 229
Study 7037159 — intervention group
Group type: COMPARATOR
Intervention: No prior irradiation (control group)
Number of subjects: 229
Study 7037159 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 229
Study 7037159 — intervention group
Group type: COMPARATOR
Intervention: No prior irradiation
Number of subjects: 229
Study 31086941 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV) with/without choroid plexus cauterization (CPC)
Number of subjects: 100
Study 31086941 — intervention group
Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt (VPS) placement
Number of subjects: 100
Study 30466484 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (text messages to support smoking cessation)
Number of subjects: 0
Study 30466484 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (national smoking cessation help line)
Number of subjects: 0
Study 30466484 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 0
Study 30466484 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 27634084 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation of the thoracic spine along with conventional physiotherapy
Number of subjects: 0
Study 27634084 — intervention group
Group type: COMPARATOR
Intervention: Conventional stretching, strengthening, and lumbar flexion exercise programme
Number of subjects: 0
Study 24657434 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored smoking prevention intervention
Number of subjects: 897
Study 24657434 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 897
Study 22226430 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT only
Number of subjects: 105
Study 22226430 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod only
Number of subjects: 105
Study 22226430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential use of PDT and imiquimod
Number of subjects: 105
Study 20731132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2a (PegIFNalpha‐2a)
Number of subjects: 24
Study 17875242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) 150-600 mg/d
Number of subjects: 1000
Study 17875242 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (GBP) 900-3600 mg/d
Number of subjects: 1000
Study 17875242 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (PGB) vs Gabapentin (GBP)
Number of subjects: 1000
Study 16172305 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure with interrupted 4‐0 nylon suture
Number of subjects: 82
Study 16172305 — intervention group
Group type: COMPARATOR
Intervention: Second intention healing
Number of subjects: 82
Study 11836333 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (E2) 1 mg orally twice daily
Number of subjects: 7
Study 10527995 — intervention group
Group type: EXPERIMENTAL
Intervention: Full planar (contour) method
Number of subjects: 57
Study 10527995 — intervention group
Group type: EXPERIMENTAL
Intervention: Three distance method
Number of subjects: 57
Study 10527995 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both methods
Number of subjects: 57
Study 7628023 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic i.m. morphine regimen calculated from the initial titrated dose
Number of subjects: 70
Study 7628023 — intervention group
Group type: COMPARATOR
Intervention: Initial i.v. morphine dose < or = 6 mg followed by paracetamol only
Number of subjects: 70
Study 7628023 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose or low-dose i.m. morphine regimen
Number of subjects: 70
Study 2035557 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin daily
Number of subjects: 36
Study 2035557 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 36
Study 31743170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 48
Study 26182947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track (FT) intervention
Number of subjects: 50
Study 26182947 — intervention group
Group type: COMPARATOR
Intervention: Standard track (ST) control
Number of subjects: 50
Study 26005878 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 49
Study 26005878 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring
Number of subjects: 49
Study 23063945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (0.3 mg/kg bolus at induction followed by 0.065 mg/kg/h for 48 hours)
Number of subjects: 90
Study 23063945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (0.3 mg/kg bolus at end of surgery followed by 0.065 mg/kg/h for 48 hours)
Number of subjects: 90
Study 23063945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 21631378 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA with IPL at 50 J/cm²
Number of subjects: 24
Study 21631378 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA with IPL at 40 J/cm²
Number of subjects: 24
Study 21631378 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA with IPL at 25 J/cm²
Number of subjects: 24
Study 21631378 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA with IPL at 20 J/cm²
Number of subjects: 24
Study 21631378 — intervention group
Group type: COMPARATOR
Intervention: Control (IPL alone)
Number of subjects: 24
Study 19178788 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (150 mg caffeine)
Number of subjects: 77
Study 19178788 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (9 mg caffeine)
Number of subjects: 77
Study 17382697 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide treatment
Number of subjects: 9
Study 14706768 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=41)
Number of subjects: 81
Study 14706768 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 81
Study 11837985 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (1 g daily)
Number of subjects: 0
Study 11837985 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (300 mg daily)
Number of subjects: 0
Study 9624885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined calcium and vitamin D supplementation (500 mg calcium and 700 IU vitamin D daily for 3 years)
Number of subjects: 389
Study 9624885 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 389
Study 8048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental services utilization by seamen
Number of subjects: 365
Study 8048325 — intervention group
Group type: COMPARATOR
Intervention: Dental services utilization by control group
Number of subjects: 365
Study 8048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Reason for last dental visit by seamen
Number of subjects: 365
Study 8048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of last dental visit by seamen
Number of subjects: 365
Study 8048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental treatment timeliness by seamen
Number of subjects: 365
Study 8048325 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions for improving dental services by seamen
Number of subjects: 365
Study 3292597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetamolol 5-10-15 mg/d (low dose)
Number of subjects: 108
Study 3292597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetamolol 15-25-50 mg/d (high dose)
Number of subjects: 108
Study 3292597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 3292597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetamolol (both doses)
Number of subjects: 108
Study 29478187 — intervention group
Group type: EXPERIMENTAL
Intervention: American ginseng (AG) extract 1 g/meal (3 g/day) for 8 weeks
Number of subjects: 24
Study 29478187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28648948 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Number of subjects: 97
Study 28648948 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic Cranial Irradiation plus Consolidative Radiation Therapy (PCI+cRT)
Number of subjects: 97
Study 25281492 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery (SCR)
Number of subjects: 975
Study 25281492 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 975
Study 24152483 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer-GP consultations directed by a self-completed checklist of needs at baseline and 3 months, GP-Toolkit to assist GPs
Number of subjects: 392
Study 24152483 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 392
Study 20972950 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ECT
Number of subjects: 53
Study 20972950 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment without ECT
Number of subjects: 53
Study 18494623 — intervention group
Group type: EXPERIMENTAL
Intervention: NOSF matrix
Number of subjects: 117
Study 18494623 — intervention group
Group type: COMPARATOR
Intervention: ORC
Number of subjects: 117
Study 16443517 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with cyclophosphamide, cisplatin, and carmustine followed by autologous hematopoietic support
Number of subjects: 425
Study 16443517 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (observation arm)
Number of subjects: 425
Study 16443517 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage high-dose chemotherapy (HDC) after partial response to AFM
Number of subjects: 425
Study 16443517 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate HDC after a complete response to AFM
Number of subjects: 425
Study 14518596 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/day
Number of subjects: 45
Study 14518596 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/day plus Clodronate (CLD) 100 mg i.m. every 10 days
Number of subjects: 45
Study 10961957 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary radiotherapy with beta-emitting (32)P source wire, 0 Gy (control)
Number of subjects: 105
Study 10961957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy with beta-emitting (32)P source wire, 16 Gy
Number of subjects: 105
Study 10961957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy with beta-emitting (32)P source wire, 20 Gy
Number of subjects: 105
Study 10961957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy with beta-emitting (32)P source wire, 24 Gy
Number of subjects: 105
Study 10961957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy
Number of subjects: 105
Study 8844502 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-potentiated desensitization (EPD)
Number of subjects: 20
Study 8844502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (buffered saline)
Number of subjects: 20
Study 8844502 — intervention group
Group type: COMPARATOR
Intervention: Mixture of allergens (open clinical trial)
Number of subjects: 20
Study 1530798 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole 1 mg/d
Number of subjects: 80
Study 1530798 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole 4 mg/d
Number of subjects: 80
Study 1530798 — intervention group
Group type: COMPARATOR
Intervention: Fadrozole (both doses)
Number of subjects: 80
Study 6383127 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil (600 mg daily)
Number of subjects: 93
Study 6383127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 31254849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 30 l/min
Number of subjects: 57
Study 31254849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 60 l/min
Number of subjects: 57
Study 30282685 — intervention group
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin (bLF) added to feeds (up to 250 mg/kg/day)
Number of subjects: 1500
Study 30282685 — intervention group
Group type: COMPARATOR
Intervention: No bLF supplementation
Number of subjects: 1500
Study 25952085 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 800
Study 25952085 — intervention group
Group type: COMPARATOR
Intervention: White-light colonoscopy
Number of subjects: 800
Study 25193471 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised moderate-intensity exercise training (n = 13)
Number of subjects: 34
Study 25193471 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (n = 8)
Number of subjects: 34
Study 25193471 — intervention group
Group type: COMPARATOR
Intervention: NAFLD patients
Number of subjects: 34
Study 23002720 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylose isomerase (XI)
Number of subjects: 65